Candidemia is the fourth most common health care-associated infection. To improve hospitalized patients’ safety, infectious disease physicians should be consulted.
Novel β-lactam/β-lactamase inhibitor combinations and cefiderocol may play a part in the treatment of infections caused by Stenotrophomonas maltophilia, Achromobacter xylosoxidans, and Burkholderia cepacia complex.
